Search

Madrigal Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

511.56 -0.97

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

513

Massimo

519.94

Metriche Chiave

By Trading Economics

Entrata

36M

-58M

Vendite

53M

364M

EPS

-1.99

Margine di Profitto

-15.906

Dipendenti

915

EBITDA

30M

-56M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+33.35% upside

Dividendi

By Acuity

Utili prossimi

3 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-583M

12B

Apertura precedente

512.53

Chiusura precedente

511.56

Notizie sul Sentiment di mercato

By Acuity

48%

52%

141 / 340 Classifica in Healthcare

Madrigal Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 ago 2026, 19:46 UTC

Madrigal Pharmaceuticals is lower in Friday's session, retracing from an earlier peak amid broader market pressures from rising Treasury yields and inflation concerns.

20 ago 2026, 23:46 UTC

Madrigal Pharmaceuticals shares are lower in after-market trading. Broader market declines are attributed to rising crude oil prices and geopolitical tensions.

18 ago 2026, 19:56 UTC

Madrigal Pharmaceuticals shares are lower today amid rising Treasury yields, which may be influencing investor sentiment. Earlier, the stock pulled back from a session high.

17 ago 2026, 19:35 UTC

Madrigal Pharmaceuticals is trading higher today, continuing gains since Friday's close, despite no specific company news driving the upward movement.

14 ago 2026, 19:26 UTC

Social Media

Madrigal Pharmaceuticals launches a Phase 2a study for resmetirom. Shares are lower today, pulled back from earlier gains amid broader market concerns over retail sales.

13 ago 2026, 21:01 UTC

Madrigal Pharmaceuticals Inc shares are higher in after-market trading, showing notable movement since Thursday's close, though no specific news explains the price action.

12 ago 2026, 21:01 UTC

Madrigal Pharmaceuticals shares are higher in after-market trading. Positive market sentiment follows comments on CPI reports that may impact Federal Reserve interest rate decisions.

10 ago 2026, 19:16 UTC

Madrigal Pharmaceuticals Inc shares are higher, despite no specific news. Broader market conditions reflect a decline in U.S. stock futures amid job data.

7 ago 2026, 20:02 UTC

Madrigal Pharmaceuticals shares are lower during Friday's session, continuing a decline since Thursday. The stock remains below its 20-day moving average.

6 ago 2026, 21:01 UTC

News

Madrigal Pharmaceuticals granted equity inducement awards to ten new employees, boosting shares modestly higher in after-market trading.

4 ago 2026, 20:04 UTC

Social Media
News

Madrigal Pharmaceuticals upgraded to Outperform by Wolfe Research, with a price target of $605. Shares are higher since Monday, despite a pullback earlier today.

3 ago 2026, 19:31 UTC

News
Social Media

Madrigal Pharmaceuticals shares are higher as CEO Bill Sibold notes market hesitance toward IVA due to weight gain concerns. The broader market also advances.

31 lug 2026, 23:06 UTC

Madrigal Pharmaceuticals Inc shares are lower in after-market hours with no specific news identified. The stock remains near the lower end of its one-month range.

30 lug 2026, 19:27 UTC

News

Madrigal Pharmaceuticals shares are lower following a widened second-quarter net loss of $57.9 million and increased operating expenses of $420.6 million.

29 lug 2026, 22:26 UTC

Madrigal Pharmaceuticals shares are lower in after-market hours, reflecting broader market volatility following the Federal Reserve's interest rate decision and inflation concerns.

28 lug 2026, 18:46 UTC

Madrigal Pharmaceuticals is lower today, continuing a broader decline since Monday's close. No specific news has been identified to explain the movement.

27 lug 2026, 23:56 UTC

Madrigal Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase since Monday's close, despite no specific news identified.

20 lug 2026, 16:02 UTC

Social Media

Madrigal Pharmaceuticals is lower today amid aggressive call buying and heightened market volume, with broader inflation concerns influenced by geopolitical tensions.

Confronto tra pari

Modifica del prezzo

Madrigal Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

33.35% in crescita

Previsioni per 12 mesi

Media 689.08 USD  33.35%

Alto 962 USD

Basso 543 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Madrigal Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

13 ratings

12

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

141 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat